结合SET7/9和CDK4抑制作用对抗骨髓瘤有协同作用
Yingxu Shi1, Zhonghao Wang2, Yiming Shao2
1Department of Orthopedics, Affiliated Hospital of Jining Medical University, Jining, Shandong, 272007, China.
Biochemical and biophysical research communications
|March 23, 2024
概括
向SET7/9 (SET域含氨酸特异性甲基转移酶7/9),通过影响CDK4-环素D1相互作用来抑制骨髓瘤细胞生长. 结合SET7/9和CDK4抑制,为骨髓瘤提供了一个有希望的,毒性较低的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 骨髓瘤是一种常见的恶性骨瘤,由于治疗选择有限,预后不佳.
- 在骨髓瘤中SET7/9 (SET域含氨酸特异性甲基转移酶7/9) 的作用尚不清楚,这阻碍了其治疗潜力.
- CDK4 (环素依赖性激酶4) 在骨髓瘤中过度表达,并与患者的不良结果有关.
研究的目的:
- 研究SET7/9在骨髓瘤扩散中的作用及其作为治疗点的潜力.
- 探索SET7/9,CDK4和骨髓瘤中细胞循环调节之间的机制联系.
- 评估SET7/9和CDK4联合抑制作为新骨髓瘤治疗策略的协同效应.
主要方法:
- 在骨髓瘤细胞中SET7/9抑制或切除.
- 对细胞增殖,细胞循环停止 (G1) 和蛋白质相互作用 (CDK4-环素 D1) 的分析.
- 在体内研究评估了SET7/9和CDK4抑制剂的联合治疗.
主要成果:
- 通过诱导G1停止,SET7/9抑制/消去抑制了骨髓瘤细胞增殖.
- 抑制SET7/9干扰了CDK4-环素D1相互作用,损害了视网母细胞瘤蛋白酸化.
- 结合SET7/9和CDK4抑制在体内表现出协同作用的抗瘤作用,剂量减少.
结论:
- 在骨肉瘤中,SET7/9通过调节CDK4-环素D1复合体作为瘤基因起作用.
- 结合SET7/9和CDK4抑制为骨髓瘤提供了一种新的,潜在的少毒性治疗策略.
- 向SET7/9可能会增强对CDK4抑制剂的敏感性,改善骨髓瘤治疗结果.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K